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Abstract
To investigate whether changes in serum lipids are associated with cognitive performance in first episode psychosis (FEP) 
patients during their first year of antipsychotic drug treatment. One hundred and thirty-two antipsychotic-treated FEP patients 
were included through the TOP study along with 83 age- and gender-matched healthy controls (HC). Information regarding 
cognitive performance, psychotic symptoms, lifestyle, body mass index, serum lipids [total cholesterol, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein cholesterol, and triglycerides] and antipsychotic treatment was obtained 
at baseline and after 1 year. The cognitive test battery is comprised of assessments for verbal learning, processing speed, 
working memory, verbal fluency, and inhibition. Mixed-effects models were used to study the relationship between changes 
over time in serum lipids and cognitive domains, controlling for potential confounders. There was a significant group by 
HDL interaction effect for verbal learning (F = 11.12, p = 0.001), where an increase in HDL levels was associated with 
improvement in verbal learning in FEP patients but not in HC. Practice effects, lifestyle, and psychotic symptoms did not 
significantly affect this relationship. Antipsychotic-treated FEP patients who increased in HDL levels during the first year of 
follow-up exhibited better verbal learning capacity. Further investigations are needed to clarify the underlying mechanisms.
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Introduction
More than 70% of patients with schizophrenia are esti-
mated to experience cognitive impairments [1]. For sev-
eral cognitive domains—including verbal learning and 
memory, attention, perception, and processing speed—the 
impairment may be as prominent as two standard devia-
tions below healthy controls [2] indicating a clinically rel-
evant decrease or deficits in cognitive functioning. These 
deficits can have a more substantial impact than positive 
psychotic symptoms in determining real-world functional 
outcome [3, 4], and may be present even after successful 
reduction in psychotic symptoms [5, 6]. Although consid-
erable efforts have been made to understand the neurobiol-
ogy of cognitive impairment in psychosis, the background 
is still mostly undetermined.
Lipids are essential for CNS development and function-
ing [7–10], including myelination and synapse communi-
cation. In schizophrenia and related psychotic disorders, 
both lipid disturbances as well as brain structural changes 
have been demonstrated. While several studies in the nor-
mal aging population, as well as in other neuropsychiatric 
disorders [11–17], characterized by compromised brain 
functioning have indicated a link between serum cho-
lesterol levels, in particular HDL cholesterol, and cog-
nition, few studies have examined the potential relation-
ship between serum lipids and cognition in patients with 
schizophrenia. In a cross-sectional study, Lancon et al. 
[18] found low HDL levels (along with hypertriglyceri-
demia, and abdominal obesity) to be related to impairment 
in verbal learning and memory. Another cross-sectional 
study [19] demonstrated that patients with schizophrenia 
and co-morbid metabolic syndrome exhibited impair-
ments in processing speed, attention/vigilance, working 
memory and problem solving, compared to those without 
metabolic syndrome. However, when the authors examined 
the different components of the metabolic syndrome, they 
found that the HDL level was positively associated with 
attention/vigilance. Also, studies in antipsychotic-treated 
patients have reported a link between serum lipids and 
cognitive performance. Krakowski and colleagues found 
that an increase in total cholesterol level and LDL level 
after a 12-week period of antipsychotic drug treatment was 
positively associated with improvements in global cogni-
tion [20] with verbal memory being the most prominent 
domain. Still, there are other studies in schizophrenia that 
have failed to show any associations between serum lipids 
and cognition [21, 22], and some have even found negative 
associations between serum lipids and cognitive perfor-
mance [23].
These discrepancies in prior studies may be due to the 
potential confounding effects of long-term medication, 
age-related neurodegeneration and disease risk-related 
environmental factors, as most previous studies have been 
focusing on chronic schizophrenia patients in a cross-sec-
tional study design. Another important limitation is a lack 
of age- and gender-matched healthy individuals to control 
for practice effects [24] and naturally occurring variations 
in serum lipid levels.
Aims of the study
The present longitudinal study of an FEP cohort was under-
taken to investigate potential associations between serum 
lipid levels and cognitive performance in the first year of 
antipsychotic treatment in a group of FEP patients with lim-
ited prior drug exposure, compared to a group of age- and 
gender-matched healthy controls (HC). We further investi-
gated the possible influence of lifestyle (smoking, alcohol, 
diet, and exercise), metabolic measures connected to serum 
lipids (body mass index), improvements in clinical symp-
tomatology secondary to antipsychotic drug treatment, and 
other illness-related factors (antipsychotic drug treatment, 
hospitalization, and depressive symptoms) on the relation-
ship between serum lipids and cognition in the patient group.
Methods and materials
Participants
The longitudinal FEP sample, recruited between 2003 and 
2013 through the Thematically Organized Psychosis (TOP) 
study (Oslo, Norway), was the same as used by Gjerde et al. 
[25]. The inclusion criteria for the TOP study were age 
between 18 and 65 years, and having a diagnosis within a 
broad schizophrenia spectrum psychosis according to the 
Diagnostic and Structural Manual of Mental Disorders, 
fourth version (DSM-IV, American Psychiatric Associa-
tion, 2000). Participants were recruited in a stable phase 
of their disorder. Exclusion criteria were current IQ under 
70, the presence of a neurological disorders or a history of 
head injuries. Additionally, for the longitudinal FEP study, 
patients who previously had received adequate antipsychotic 
drug treatment were not recruited [25]. Healthy controls 
(HC) were randomly selected and recruited from the same 
geographic catchment area as the patients, using national 
statistical records (2003–2011). They were matched for age 
and gender. To ensure a reliable HC sample, subjects were 
excluded if they or any of their first-degree relatives had 
a history of a severe psychiatric disorder as indicated by 
the Primary Care Evaluation of Mental Disorders [26]. The 
final sample consisted of 132 first episode psychosis (FEP) 
patients and 83 HC. Participants were tested at baseline 
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and after 1 year. None of the participants used medication 
against thyroid problems, diabetes, hypertension or choles-
terol-lowering medications (statins or fibrates).
All participants gave written informed consent prior to 
their inclusion in the study, and the Regional Ethics Com-
mittee and The Norwegian Data Inspectorate approved the 
study.
Clinical assessments
Demographic and clinical data (including antipsychotic drug 
treatment) were obtained through structured interviews and 
from hospital medical records. The diagnosis was estab-
lished by use of the Structural Clinical Interview for DSM-
IV (SCID) [27]. Psychotic symptoms were assessed with 
the Positive and Negative Syndrome Scale (PANSS) [28] 
and depressive symptoms with the Calgary Depression Scale 
for Schizophrenia (CDSS) [29]. Remission was defined as 
at least 1 week with no score of ≥ 4 on any of the following 
five PANSS items: P1, P3, P5, P6, or G9. Alcohol use was 
measured with the Alcohol Use Disorders Identification Test 
(AUDIT) [30]. Information on diet and exercise habits for 
the FEP patients was obtained by self-assessment at baseline 
and follow-up. Patients were asked to describe their eating 
habits as healthy, moderately healthy or unhealthy, while 
exercise was initially assessed as light, moderate or hard. 
Diet was then dichotomized into “similar or poorer diet” 
(including patients who did not change their diet habits from 
inclusion to 12 months, as well as patients who reported 
a poorer diet at 12 months) and “better diet” (consisting 
of patients who reported a beneficial change in diet). Exer-
cise was likewise dichotomized into “similar or reduced 
exercise” and “increased exercise” at 12 months (for more 
details, see [25]).
Antipsychotic drug treatment in the FEP group
As we did not have sufficient statistical power to create sepa-
rate subgroups for the different antipsychotic agents (see 
supplementary Tables 1, 2 and 3 for antipsychotic use), we 
Table 1  Demographic, metabolic, and cognitive characteristics of the FEP and HC sample
p values are obtained from T tests and chi-square test
p values in bold indicate numbers that are significant on the 95% confidence limit
FEP first episode psychosis, HC healthy controls, SD standard deviation, n number of subjects, % percentage, AUDIT Alcohol Use Disorder 
Identification Test, DUP duration of untreated psychosis, PANSS Positive and Negative Syndrome Scale, CDSS Calgary Depression Scale for 
Schizophrenia
a Diet was divided into “similar or poorer” and “better” compared to diet habits at baseline
b Exercise was divided into “similar or reduced” and “increased” compared to exercise habits at baseline
c “Continuous antipsychotic drug use” refers to the continuous use of any antipsychotic agent during the study period
d “Intermittent antipsychotic drug use” refers to the use of any antipsychotic agent, either at baseline or 12 months
FEP (n) HC (n) FEP, mean (SD) HC, mean (SD) t p value
Age (years) 132 83 26.7 (7.6) 29.0 (6.8) − 2.6 0.01
Education (years) 132 83 12.9 (2.8) 14.2 (2.0) − 4.43 < 0.001
Alcohol use (AUDIT scores) 120 71 7.3 (7.4) 5.9 (3.0) 1.89 0.06
DUP (weeks), median (range) 132 40.0 (1–1040)
Total PANSS scores 132 63.2 (13.9)
PANSS-positive subscores 132 2.6 (1.0)
PANSS-negative subscores 132 2.2 (1.0)
Depressive symptoms (CDSS scores) 128 6.2 (4.5)
FEP (n) HC (n) FEP, n (%) HC, n (%) X2 p value
Gender (male) 132 83 85 (64.4) 80 (59.7) 0.62 0.45
Ethnicity (Caucasian) 132 83 87 (65.9) 132 (98.3) 52.32 < 0.001
Smoking (daily) 132 86 60 (45.5) 17 (19.8) 15.04 < 0.001
Hospitalization at inclusion 132 30 (22.7)
Change in diet (“better diet”)a 132 20 (15.2)
Change in exercise (“increased exercise “)b 129 21 (15.9)
Continuous antipsychotic drug  usec 132 100 (76)
Intermittent antipsychotic drug  used 132 32 (24)
Antipsychotic monotherapy 132 91 (69)
Antipsychotic polypharmacy 132 41 (31)
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organized data on antipsychotic medication as “continuous 
antipsychotic drug use” versus “intermittent antipsychotic 
drug use” [25]. Continuous use was defined as using any 
antipsychotic agent at baseline and at 12 months (not nec-
essarily the same agent at both time points), while inter-
mittent use was defined as using any antipsychotic agent at 
either baseline or at 12 months. In addition, we differenti-
ated between antipsychotic monotherapy (using only one 
antipsychotic at the specific time point) and polypharmacy 
(using two or more antipsychotic agents at the same time 
point). All patients who used first-generation drugs also used 
second-generation drugs, and due to insufficient information 
regarding switches and duration of antipsychotic treatments 
during the follow-up period, it was not possible to calculate 
cumulative drug exposure.
Table 2  Mixed models 
examining serum lipids, BMI 
and cognitive performance at 
baseline in FEP and HC
p values in bold indicate numbers that are significant on the 95% confidence limit
Verbal learning was measured with California Verbal Learning Test, processing speed with Digit Symbol 
Test, working memory with Letter number span, verbal fluency with Verbal Fluency Test, and inhibition 
with Color-Word Interference Test. Analyzed with mixed-effects models while controlling for age, gender, 
education, and group (FEP vs. HC). The HC were defined as the reference group
FEP first episode psychosis, HC healthy controls, SD standard deviation, F F value, B regression coef-
ficient, SE standard error of the regression coefficient, HDL high-density lipoprotein cholesterol, LDL low-
density lipoprotein cholesterol, Ln TG Ln of triglycerides, BMI body mass index
FEP, mean (SD) HC, mean (SD) Group Group
F p value B SE (B)
Total cholesterol (mmol/L) 4.97 (1.00) 4.59 (0.90) 8.94 0.003 0.39 0.13
HDL (mmol/L) 1.39 (0.40) 1.44 (0.43) 0.08 0.79
LDL (mmol/L) 2.99 (0.82) 2.59 (0.81) 11.54 0.001 0.38 0.11
Ln TG (mmol/L) 0.81 (0.31) 0.77 (0.26) 0.82 0.37
BMI (kg/m2) 24.9 (4.3) 24.1 (3.7) 1.57 0.21
Verbal learning (total scores) 49.31 (11.80) 59.22 (8.54) 35.25 < 0.001 − 8.82 1.48
Processing speed (total scores) 60.40 (16.82) 79.55 (13.32) 65.19 < 0.001 − 16.77 2.08
Working memory (total scores) 9.21 (2.61) 11.89 (2.40) 48.33 < 0.001 − 2.50 0.36
Verbal fluency (total scores) 35.58 (14.54) 45.39 (9.98) 18.27 < 0.001 − 7.65 1.79
Inhibition (total scores) 66.07 (24.14) 49.52 (10.83) 27.75 < 0.001 15.08 2.86
Table 3  Mixed models 
examining serum lipid, BMI 
and cognitive trajectories over 
1 year in FEP and HC
p values in bold indicate numbers that are significant on the 95% confidence limit
Verbal learning was measured with California Verbal Learning Test, processing speed with Digit Symbol 
Test, working memory with Letter number span, verbal fluency with Verbal Fluency Test, and inhibition 
with Color-Word Interference Test. Analyzed with mixed-effects models examining a time × group interac-
tion while controlling for age, gender, education, time, and group (FEP vs. HC). The HC were defined as 
the reference group
FEP first episode psychosis, HC healthy controls, F f value, B regression coefficient, SE standard error of 
the regression coefficient, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein choles-
terol, Ln TG ln of triglycerides, BMI body mass index
Time Group × time Group × time
F p value F p value B SE (B)
Total cholesterol (mmol/L) 0.005 0.94 0.003 0.96
HDL (mmol/L) 2.77 0.10 2.24 0.14
LDL (mmol/L) 0.32 0.57 1.48 0.23
Ln TG (mmol/L) 0.05 8.39 0.05 0.82
BMI (kg/m2) 23.84 < 0.001 6.99 0.01 0.95 0.36
Verbal learning (total scores) 17.60 < 0.001 6.86 0.01 3.54 1.35
Processing speed (total scores) 0.05 0.003 2.27 0.13
Working memory (total scores) 0.10 0.75 0.10 0.75
Verbal fluency (total scores) 0.21 0.65 6.38 0.01 − 3.15 1.25
Inhibition (total scores) 0.60 0.02 0.37 0.54
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Cognitive tests
The cognitive test battery is comprised of five cognitive 
domains (verbal learning, processing speed, working mem-
ory, verbal fluency, and inhibition) based on previous find-
ings related to cognitive dysfunction in FEP patients [31].
Psychologists trained in standardized neuropsychologi-
cal testing carried out the cognitive assessment. Current IQ 
was estimated from the Wechsler Adult Intelligence Scale 
(WASI); subscale similarities and block design. Verbal 
learning was measured with the California Verbal Learning 
Test (CVLT-II) [32], verbal learning sub-score. Processing 
speed was measured with the Digit Symbol Test [33]. Work-
ing memory was measured with the Letter number sequenc-
ing test [33]. Verbal fluency was measured with the Verbal 
Fluency Test, phonetic sub-score from the Delis–Kaplan 
Executive Functioning System (D-KEFS) [34]. Finally, inhi-
bition was measured with the Color-Word Interference Test 
from the D-KEFS [34], inhibition sub-score. Raw scores 
were reported for all tests to be able to calibrate the cogni-
tive performance of the FEP patients compared to a repre-
sentative age- and gender-matched HC group from the same 
catchment area as the patients. Higher scores indicated better 
performance on all tests except for the inhibition sub-test 
where higher scores indicated poorer performance. All par-
ticipants showed an adequate neuropsychological test effort 
indicated by two errors or less on the forced recognition 
trial of the California Verbal Learning Task (CVLT-II) [32].
Serum lipids and BMI
Blood was drawn from the antecubital vein in the morning 
after overnight fasting at baseline and 12 months, on the 
same day as the neuropsychological testing took place (time 
period: 2003–2013). The Department of Clinical Chemis-
try at Oslo University Hospital, using standard enzymatic 
methods from Roche Diagnostics Norge AS (Oslo, Norway), 
analyzed cholesterol (total, HDL, LDL) and triglycerides 
(TG). All blood samples were sent immediately after collec-
tion and analyzed continuously as routine samples. Digital 
weights were used to weight all the participants and body 
mass index (BMI) calculated accordingly: BMI = weight (in 
kilograms) divided by height (in meters squared) (kg/m2).
Statistical analyses
The data were analyzed with SPSS version 23 (SPSS Inc., 
Chicago, IL, USA/IBM, New York, USA). The level of sta-
tistical significance was preset to p < 0.05 (two tailed). For 
the comparison of demographic characteristics, chi-square 
tests and t tests were used as appropriate.
For the main analyses, we employed linear mixed models 
with unstructured covariance matrix to examine longitudinal 
changes and between-group effects of lipid measures on 
cognitive measures. Preliminary analyses were conducted 
to ensure assumptions of normality, linearity, multicollin-
earity, and homoscedasticity. Serum TG values were ln-
transformed after inspection of residuals. Due to issues with 
multicollinearity, we did not enter all the lipids in the same 
mixed model analysis. There were no problems with linear-
ity or homoscedasticity.
In separate mixed models, we first examined any baseline 
differences in metabolic and cognitive measures controlling 
for age, gender, and education. Then, we explored the 1-year 
changes in serum lipids, BMI, and cognitive performance. 
In the latter longitudinal models, we also included time and 
a group (FEP and HC) × time interaction.
Our approach to the interpretation of statistical results 
obtained from the cognitive models was that a main effect 
of time would indicate cognitive changes due to drug treat-
ment or other causes (i.e., practice effects). To disambiguate 
the latter two possibilities, we would compare the cognitive 
performance of the patient group with that of the HC group. 
Group × time interactions that favored steeper improvement 
in the FEP group would be viewed as an indication of a 
possible treatment effect, reflecting cognitive enhancement. 
A main effect for time in the absence of such an interaction 
could be regarded as representing practice effects.
The mixed models that displayed a significant 
group × time interaction were subsequently examined for 
a potential relationship with serum lipids. The rationale for 
this was that group-specific changes to cognition might be 
related to alterations in serum lipids due to antipsychotic 
drug treatment. In these mixed models, the scores from the 
specific cognitive tests were defined as dependent variables, 
while time (baseline and 12 months), age, gender, years of 
education, group affiliation (FEP or HC), and serum lipids 
were entered as independent variables. To investigate if there 
was a group-dependent effect of lipids on cognition, we also 
included a group × lipid interaction.
In post hoc analyses, using similar mixed models as 
in our main analyses, we further examined if any group-
specific lipid effects on cognition could be explained by 
ethnicity, lifestyle-related factors (smoking, alcohol, diet, 
and exercise), concomitant changes in BMI, be secondary 
to antipsychotic treatment effects on positive and negative 
symptoms, remission status at 12 months, or be explained 
by other illness-related factors (hospitalization and depres-
sive symptoms).
Missing data
Preliminary analyses indicated a random distribution of 
the missing variables and that there were no significant dif-
ferences in sociodemographic characteristics or cognitive 
test scores between the subjects with a complete dataset on 
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serum lipids compared to the ones with missing data (Lit-
tle’s MCAR test: chi-square = 1912.51, df = 1865, p = 0.22). 
Forty-seven (36%) of the FEP patients lacked cognitive 
data at follow-up. These FEP patients were included in the 
main analyses because they had baseline data and a mixed 
linear model approach using all available information was 
employed. As a precaution, we also checked the validity of 
our results by repeating the analyses excluding participants 
with an incomplete dataset.
Results
For a detailed description of demographic characteristics 
and group comparison of FEP with HC, see Table 1. In sum-
mary, the FEP patients had significantly shorter education, 
more non-Caucasian ethnicity and a higher percentage of 
daily smokers, compared to the HC.
Group differences in serum lipids at baseline 
and after 1 year of follow‑up
As described in Table 2, the FEP patients had significantly 
higher levels of total cholesterol and LDL compared to 
the HC at baseline, (F = 8.94, p = 0.003) and (F = 11.54, 
p = 0.001), respectively. During the follow-up, there were 
no significant changes in mean levels of serum lipids among 
the FEP patients when compared to the HC at the group level 
(Table 3). Still, there were individual differences, and at the 
individual level the serum lipid changes for the FEP were the 
following: 47 participants (47%) experienced a decrease and 
52 participants (53%) an increase in their total cholesterol 
levels; 49 participants (54%) experienced a decrease and 
41 participants (46%) an increase in their HDL levels; 43 
participants (50%) experienced a decrease and 43 partici-
pants (50%) an increase in their LDL levels; 40 participants 
(45%) experienced a decrease and 49 participants (55%) an 
increase in their TG levels.
Group differences in cognition at baseline 
and after 1 year of follow‑up
The FEP patients demonstrated marked impairments in cog-
nitive functioning across all domains at baseline (p < 0.001) 
(Table 2). During the 1-year follow-up, there was a main 
effect of time (F = 17.60, p < 0.001) (indicating signifi-
cant changes in cognitive performance from baseline to 
12 months) as well as a group by time interaction for ver-
bal learning (F = 6.86, p = 0.01), with a steeper change in 
FEP compared to HC (B = 3.54, p = 0.01), indicating that 
practice effects alone cannot explain the relatively higher 
improvement in patients compared to HC. The mixed model 
analyses also showed a group by time interaction for verbal 
fluency (F = 6.38, p = 0.01); here, the FEP group exhibited a 
deterioration in comparison with the HC group, (B = − 3.15, 
p = 0.01), respectively.
Association between serum lipids and cognition
When examining the two cognitive domains that showed a 
group by time interaction (verbal learning and verbal flu-
ency) for associations with serum lipid levels, we found that 
there was a significant group by HDL interaction effect for 
verbal learning (F = 11.12, p = 0.001), where an increase 
in HDL level was related to improvement in verbal learn-
ing among FEP patients compared to the HC (B = 10.32, 
p = 0.001). Verbal fluency, in contrast, did not evidence any 
significant group by lipid interactions. Follow-up analyses 
excluding patients with incomplete cognitive datasets pro-
duced comparable results (data not shown).
Because the FEP patients, in contrast to HC, included 
several subjects with their primary education outside Nor-
way, which could influence the cognitive test scores, we also 
reran the analyses without these patients and obtained simi-
lar results as in our main analyses (data not shown).
Post hoc analyses exploring the significant 
associations found between serum lipids 
and cognition
The post hoc mixed models controlling for antipsychotic 
usage (i.e., continuous use vs. intermittent use), and positive 
and negative symptoms indicated that the group (i.e., FEP)-
specific link between HDL and verbal learning remained 
highly significant (F = 7.45, p = 0.007). A significant main 
effect of positive symptoms (F = 4.67, p = 0.03) and nega-
tive symptoms (F = 11.77, p = 0.001), but not for antipsy-
chotic drug use (F = 1.03, p = 0.31), was also exhibited. As 
the magnitude of the effect is reflected in the standardized 
regression coefficients, we examined these coefficients to 
discern whether HDL cholesterol had a stronger impact 
than negative and positive symptoms on verbal learning. 
Our results indicated that HDL (B = 3.13, p = 0.007) was 
a stronger predictor for verbal learning than were negative 
(B = − 2.20, p = 0.001) and positive symptoms (B = − 1.76, 
p = 0.03). Likewise, controlling for remission status did not 
significantly impact the observed link between serum HDL 
and verbal learning in the FEP group (B = 8.42, p = 0.002).
We further investigated the influence of antipsychotic 
drug treatment (continuous use vs. intermittent use, and 
antipsychotic monotherapy vs. polypharmacy) on the rela-
tionship between HDL levels and verbal learning. The 
group (FEP)-specific HDL-link remained highly significant, 
(F = 10.76, p = 0.001) and (F = 10.54, p = 0.001), whereas 
the main effect of antipsychotic drug treatment was absent, 
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inferring limited value to differential treatment effects on the 
observed link between HDL and verbal learning.
Furthermore, though there was a main effect of BMI on 
verbal learning (F = 4.88, p = 0.03), the group by HDL inter-
action remained significant (F = 9.86, p = 0.002) indicating 
that the link between HDL and verbal learning was inde-
pendent of BMI. Of note, ethnicity, hospitalization, depres-
sive symptoms, smoking habits, diet, exercise, and alcohol 
use demonstrated no attenuation of results for the observed 
link between HDL and verbal learning (data not shown).
Discussion
The current study of antipsychotic-treated FEP patients 
showed that during the first year of follow-up, an increase 
in serum HDL was associated with better verbal learning 
capacity. This relationship was independent of practice effect 
(as controlled by a group of age- and gender-matched HC), 
lifestyle, concurrent changes in BMI, and improvements in 
clinical symptomatology. Having in mind that cognitive per-
formance is an important predictor of longitudinal clinical 
and functional outcomes in patients with psychotic disor-
ders, our findings may be of clinical relevance.
Consistent with prior literature [35], the FEP patients per-
formed poorer on all cognitive tests compared to the HC. 
During the follow-up, there was a group-specific improve-
ment in verbal learning, which subsequent analyses showed 
was associated with an increase in HDL levels among the 
FEP patients but not amongst HC. Our findings are in line 
with Lancon and colleagues [18] finding a positive asso-
ciation between HDL and verbal learning and memory in 
a cross-sectional sample of chronic schizophrenia patients. 
The present study is, however, the first to report such an 
association in a cohort of FEP patients with age- and gender-
matched healthy controls.
The observed link between HDL and cognition is also 
consistent with the mechanisms that relate lipids to the brain 
while also agreeing with evidence of impaired lipid metabo-
lism (including cholesterol) in psychotic patients [36–40]. 
Lipids are not only essential for myelination; synaptic 
growth and regeneration also depend greatly on the avail-
ability of brain cholesterol [41, 42]. Depletion of cholesterol 
in tissue cultures has, for example, been shown to inhibit 
synaptogenesis and causes neurodegenerative changes [42]. 
Brain structures such as the hippocampus express high 
transcript levels of lipid-biosynthesizing enzymes [42], are 
densely populated by synapses, and play a prominent role in 
verbal learning and memory [43, 44]. Several studies have 
found a positive link between performances on verbal learn-
ing and hippocampal volumes [45–47], as well as on distinct 
subfield volumes [48]. More importantly, a growing num-
ber of evidence in the normal aging population and patients 
with neuropsychiatric disorders, points to high serum HDL 
levels, in particular, being protective against hippocampal 
atrophy [49]. This dependency of the hippocampus on intact 
cholesterol metabolism may at least in parts explain our find-
ing of a distinct link between HDL cholesterol and the hip-
pocampus-based task of verbal learning. While studies are 
reporting a correlation between different cognitive domains 
within an individual [50–55], there are several investigators 
that have emphasized a cognitive architecture best described 
by relatively independent cognitive domains [2, 56–58], 
and verbal learning is recognized as one such independent 
cognitive dimension. In further support of distinguishable 
cognitive dimensions is the fact that pharmacological inter-
ventions, including antipsychotic drug treatment, have been 
shown to cause changes in specific cognitive domains [59], 
indicating a pharmacological dissociation of certain groups 
of cognitive processes.
For decades, the traditional view has been that the cho-
lesterol in the brain is synthesized de novo; newer evidence, 
however, suggests that excessive cholesterol synthesis may 
be regulated by intricate efflux mechanisms linking central 
and peripheral cholesterol levels [60–63]. Indeed, serum 
HDL has been found to be highly correlated with HDL in 
cerebrospinal fluid [64]. Still, the nature of this relationship, 
between serum lipids and lipids in the CNS, is not fully elu-
cidated. It is, however, likely that long-term lipid status may 
have a different impact on brain structure and functioning 
than the short-term impacts observed in treatment studies 
[19, 20, 65], and that these changes in brain structure and 
functioning may be more pronounced in the developmental 
lifespan [66]. While we included a relatively young FEP 
population (with a mean age of 25 years), future studies may 
consider including high-risk patients, as well as having a 
longer study period with frequent observation points.
We recently demonstrated that an increase in HDL during 
antipsychotic drug treatment was related to an improvement 
in negative symptoms in the same FEP cohort [25]. Other 
studies have shown a relationship between negative symp-
toms and verbal learning [67]. As we now find HDL levels 
being associated with specific cognitive domains, it is plau-
sible that improvements in cognitive functioning over time 
were more related to clinical symptom improvement, reflect-
ing “pseudospecificity” [68]. Additionally, lack of motiva-
tion and motor retardation inherent in the negative syndrome 
could also have disturbed test performance in patients with 
prominent negative symptoms. We attempted to disentangle 
these phenomena by controlling for secondary changes in 
negative (and positive) symptoms during antipsychotic drug 
treatment, obtaining similar results as in our main analy-
ses. Intriguingly, the standardized regression coefficients 
revealed that the HDL level was more profoundly related to 
working memory than positive and negative symptoms were, 
adding support to the growing literature on the role of lipids 
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in psychotic disorders. Also, other factors that are known to 
influence cholesterol metabolism as well as cognitive func-
tion such as lifestyle and behavioral factors [69–73] were 
controlled for in the post hoc analyses, achieving similar 
results as in our main analyses.
The present study has some additional limitations that 
need to be addressed. The constitution of the HC group 
was different from the FEP group since the latter included 
subjects with their primary education from outside Norway, 
which could influence cognitive performance especially for 
verbal tests. We tried to minimize the effect of this limitation 
by controlling for education in the mixed model analyses. 
Also, we reran the analyses excluding the patients without a 
Norwegian education, generating similar results. Information 
on diet and exercise habits was only available for FEP but not 
for HC. Additionally, self-assessment about diet and exercise 
may be problematic as it may be linked to high social desira-
bility; on the other hand, achieving truly reliable data on these 
parameters may be difficult outside the confinement of an 
institution. Due to power issues, we were not able to examine 
specifically and compare different antipsychotic agents and 
how this may influence our results. Still, our main objective 
was to examine the effect of serum lipids per se on cognition 
in FEP patients, and for this particular aim, differentiating 
the antipsychotic agents might be less prudent. We further 
recognize that other factors then practice can explain a main 
effect of time: the controls are healthy, and could in theory 
be susceptible to a ceiling effect in the amount of change 
that can be achieved; leading to potential differences in the 
learning potential in the two groups. While an untreated con-
trol group may have been ideal to address this matter, it is 
not ethically feasible. Finally, as our study is naturalistic in 
design, temporality cannot be established, and studies with a 
randomized controlled design, which include treatment tar-
geted explicitly at elevating HDL levels and measurements of 
change in cognitive performance, are necessary.
In conclusion, the present study of antipsychotic-treated 
FEP patients showed that during the first year of follow-up, 
an increase in serum HDL was associated with better cog-
nitive performance. Further research, implementing clini-
cal data with for instance myelin-focused brain imaging 
techniques, is warranted. As cognitive deficits dramatically 
impact social and occupational functioning, our findings 
of a link between HDL and cognition could potentially 
contribute to the development of new treatment strategies, 
with functional improvements achieved by increasing HDL 
levels as an add-on treatment for cognitive remediation 
that has shown to be effective in patients with psychosis.
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